Boston Therapeutics, Inc. Gets First Sales of SUGARDOWN™ in Italy  
1/3/2012 7:15:06 AM

MANCHESTER, N.H.--(BUSINESS WIRE)--Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today that it has secured its first purchase order for distribution of SUGARDOWN™ in Italy.

"We are very pleased to announce the first purchase order for SUGARDOWN™ and the introduction of our chewable dietary supplement for glycemic health to the Italian market. With the help of our distributor, SUGARDOWN™ is now listed on Codifa, a national registry for pharmaceuticals in Italy”, said Ken Tassey, President and Chief Operations Officer of Boston Therapeutics.